<DOC>
	<DOCNO>NCT01624636</DOCNO>
	<brief_summary>This study ass safety , tolerability , pharmacokinetics , pharmacodynamics , efficacy successive intravenous ( IV ) dose LFG316 eligible patient neovascular age-related macular degeneration ( AMD )</brief_summary>
	<brief_title>Safety Tolerability Intravenous LFG316 Wet Age-related Macular Degeneration ( AMD ) .</brief_title>
	<detailed_description />
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Wet Macular Degeneration</mesh_term>
	<criteria>Active choroidal neovascular AMD least one eye . Retinal disease AMD , investigator 's opinion , would interfere safety study conduct . Choroidal neovascularization due cause AMD . In study eye , medium opacity , investigator 's opinion , would interfere study conduct . Any disease concomitant ( recent ) medication expect cause systemic immunosuppression . History meningococcal meningitis past 10 year , history recurrent meningitis . History hospitalization pneumococcal pneumonia within past 3 year . History serious systemic infection within past 12 month . Any following treatment study eye within 7 day prior study drug dosing : ranibizumab ( Lucentis ) , bevacizumab ( Avastin ) , pegaptanib ( Macugen ) , VEGF inhibitor . Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>AMD</keyword>
	<keyword>Age-related Macular Degeneration</keyword>
	<keyword>Wet AMD</keyword>
	<keyword>Neovascular AMD</keyword>
</DOC>